Related Experiment Video
Updated: Jan 16, 2026
07:13
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
936
Receptor-Interacting Protein Kinase 1 (RIPK1): A Potential Therapeutic Target in Ischemic Stroke.
Zijun Liu1, Fenglian Xu1, Ziyu Wang1
1Department of Basic Medicine, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Tongjiaxiang 24, Nanjing, 210009, People's Republic of China.
Molecular Neurobiology
|January 14, 2026
Summary
Receptor-interacting protein kinase 1 (RIPK1) is crucial in ischemic stroke by regulating cell death and inflammation. Understanding RIPK1
Area of Science:
- Molecular Biology
- Neuroscience
- Pathology
Background:
- Receptor-interacting protein kinase 1 (RIPK1) is a key regulator of cell death and inflammation.
- RIPK1's role in ischemic stroke is not fully understood, despite its known involvement in other diseases.
- Post-translational modifications significantly influence RIPK1 activity and function.
Purpose of the Study:
- To review the molecular structure, functions, and regulatory networks of RIPK1.
- To elucidate the mechanisms of RIPK1 in ischemic stroke pathology.
- To discuss RIPK1 inhibitors for potential therapeutic applications in ischemic stroke.
Main Methods:
- Literature review summarizing current research on RIPK1.
- Analysis of RIPK1's involvement in cell death pathways (apoptosis, necroptosis).
- Examination of RIPK1's role in neuroinflammation and NF-κB activation.
- Review of RIPK1's impact on blood-brain barrier integrity.
- Overview of RIPK1 inhibitor development and clinical trials.
Main Results:
- RIPK1 modulates apoptotic and necroptotic cell death cascades in ischemic stroke.
- RIPK1 contributes to neuroinflammation and NF-κB pathway activation, influencing stroke outcome.
- RIPK1 plays a role in maintaining blood-brain barrier integrity.
- RIPK1 shows potential as a diagnostic marker for ischemic brain injury.
Conclusions:
- RIPK1 is a critical mediator in ischemic stroke, impacting cell death, neuroinflammation, and BBB integrity.
- Targeting RIPK1 presents a promising therapeutic strategy for ischemic stroke.
- Further research into RIPK1 regulation and inhibitor development is warranted for clinical translation.
Related Concept Videos
01:31Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:20The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
01:26Receptor Tyrosine Kinases
18.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.0K
01:22Amplifying Signals via Enzymatic Cascade
17.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
17.3K